Telix Pharmaceuticals Ltd traded at 6.73 this Wednesday March 29th, decreasing 0.08 or 1.17 percent since the previous trading session. Looking back, over the last four weeks, Telix Pharmaceuticals Ltd lost 0.59 percent. Over the last 12 months, its price rose by 56.88 percent. Looking ahead, we forecast Telix Pharmaceuticals Ltd to be priced at 6.64 by the end of this quarter and at 6.15 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Cochlear 229.62 -0.69 -0.30% 3.08%
CSL 283.55 -1.45 -0.51% 5.00%
Integral Diagnostics Ltd 2.89 -0.02 -0.69% -27.39%
Mesoblast Ltd 0.94 0.01 1.08% -17.98%
Mayne Pharma 3.63 -0.13 -3.46% -20.59%
Opthea Ltd 0.74 -0.02 -2.65% -32.88%
Paradigm Biopharmaceuticals Ltd 1.37 0.02 1.11% 27.44%
Pacific Edge 0.41 0 0% -57.73%
Polynovo Ltd 1.72 -0.08 -4.18% 52.21%
PYC Therapeutics Ltd 0.07 -0.001 -1.47% -31.63%
Ramsay Health Care 65.08 0.41 0.63% 0.53%
ResMed 31.81 -0.41 -1.27% -2.96%
Sonic Healthcare 34.53 0.04 0.12% -3.52%

Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Limited is a radiopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) to treat cancer. In MTR therapy, a radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The radioactive payload can either be diagnostic (for imaging) or therapeutic, or both. Its lead programs include TLX591-CDx (Illuccix) / TLX591 for diagnosis and treatment of metastatic castrate-resistant prostate cancer, TLX250-CDx/TLX250 for diagnosis and treatment of renal (kidney) cancer, TLX101-CDx / TLX101 for diagnosis and treatment of glioblastoma (brain cancer), and TLX66-CDx (Scintimun) / TLX66 for the treatment of bone marrow conditioning and rare diseases.